We are live on
!
Find out more
PM
Prosight Management Portfolio holdings
AUM
$580M
1-Year Est. Return
29.81%
This Fund
S&P 500
This Quarter
Est. Return
+7.6%
1 Year Est. Return
+29.81%
3 Year Est. Return
+39.55%
5 Year Est. Return
-6.93%
10 Year Est. Return
–
AUM
$179M
AUM Growth
+$42.9M
(+31%)
Cap. Flow
+$32.6M
Cap. Flow
% of AUM
18.19%
Top 10 Holdings %
Top 10 Hldgs %
60.25%
Holding
43
New
12
Increased
10
Reduced
10
Closed
11
Avg Time Held Equity + Options
1.3
quarters
Top 10 Avg Time Held Equity + Options
0.9
quarters
Top 20 Avg Time Held Equity + Options
1.6
quarters
Avg Time Held Equity only
1.4
quarters
Top 10 Avg Time Held Equity only
0.9
quarters
Top 20 Avg Time Held Equity only
1.6
quarters
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
HNGR
Hanger Inc.
HNGR
|
+$26M |
| 2 |
Zimmer Biomet
ZBH
|
+$7.83M |
| 3 |
ModivCare
MODV
|
+$5.92M |
| 4 |
ALBO
Albireo Pharma Inc
ALBO
|
+$5.33M |
| 5 |
ARNA
Arena Pharmaceuticals Inc
ARNA
|
+$4.24M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Cigna
CI
|
+$8.93M |
| 2 |
AGN
Allergan plc
AGN
|
+$7.4M |
| 3 |
ATHN
Athenahealth, Inc.
ATHN
|
+$6.55M |
| 4 |
Cidara Therapeutics
CDTX
|
+$3.68M |
| 5 |
MacroGenics
MGNX
|
+$3.43M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 98.36% |
| 2 | Miscellaneous | 1.64% |
| 3 | Industrials | 0% |
| 4 | Real Estate | 0% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | Held Since | |
|---|---|---|---|---|---|---|---|
|
HNGR
1
DELISTED
Hanger Inc.
HNGR
| $25M | 13.93% |
+1,199,602
| New | +$26M |
2018 Q3
0 quarters
|
|
|
TLGT
2
DELISTED
Teligent, Inc
TLGT
| $12.8M | 7.14% |
324,076
-8,424
| -3% | -$338K |
2018 Q1
2 quarters
|
|
|
ARNA
3
DELISTED
Arena Pharmaceuticals Inc
ARNA
| $11.2M | 6.26% |
244,050
+104,522
| +75% | +$4.24M |
2018 Q1
2 quarters
|
|
|
4
MacroGenics
MGNX
$218M
| $9.81M | 5.47% |
457,475
-161,040
| -26% | -$3.43M |
2017 Q4
3 quarters
|
|
5
BioMarin Pharmaceuticals
BMRN
$10.5B
| $9.35M | 5.21% |
96,428
+38,528
| +67% | +$3.85M |
2018 Q1
2 quarters
|
|
6
Palvella Therapeutics
PVLA
$1.85B
| $9.31M | 5.19% |
20,774
+3,774
| +22% | +$1.64M |
2018 Q1
2 quarters
|
|
|
7
Zimmer Biomet
ZBH
$17.6B
| $8.4M | 4.69% |
+65,848
| New | +$7.83M |
2018 Q3
0 quarters
|
|
8
Iovance Biotherapeutics
IOVA
$6.57B
| $8.05M | 4.49% |
715,317
+275,417
| +63% | +$3.91M |
2017 Q4
3 quarters
|
|
9
Indaptus Therapeutics
INDP
$318M
| $7.55M | 4.21% |
597
+95
| +19% | +$903K |
2018 Q2
1 quarter
|
|
|
RETA
10
DELISTED
Reata Pharmaceuticals, Inc. Class A Common Stock
RETA
| $6.55M | 3.65% |
80,155
-2,939
| -4% | -$207K |
2017 Q4
3 quarters
|
|
|
11
Cigna
CI
$74.7B
| $6.09M | 3.39% |
29,236
-48,164
| -62% | -$8.93M |
2018 Q1
2 quarters
|
|
|
AGN
12
DELISTED
Allergan plc
AGN
| $5.98M | 3.34% |
31,400
-40,300
| -56% | -$7.4M |
2017 Q4
3 quarters
|
|
|
13
DELISTED
ModivCare
MODV
| $5.73M | 3.2% |
+85,217
| New | +$5.92M |
2018 Q3
0 quarters
|
|
|
ALBO
14
DELISTED
Albireo Pharma Inc
ALBO
| $5.37M | 2.99% |
+162,905
| New | +$5.33M |
2018 Q3
0 quarters
|
|
15
Viking Therapeutics
VKTX
$3.39B
| $4.78M | 2.67% |
+274,410
| New | +$3.27M |
2018 Q3
0 quarters
|
|
|
SRRA
16
DELISTED
Sierra Oncology, Inc. Common Stock
SRRA
| $4.62M | 2.58% |
68,002
+22,838
| +51% | +$2.07M |
2018 Q1
2 quarters
|
|
17
Assembly Biosciences
ASMB
$414M
| $4.44M | 2.48% |
9,965
+4,523
| +83% | +$2.12M |
2018 Q2
1 quarter
|
|
18
Kura Oncology
KURA
$874M
| $4.44M | 2.48% |
253,631
-34,256
| -12% | -$657K |
2018 Q2
1 quarter
|
|
|
SHPG
19
DELISTED
Shire pic
SHPG
| $4.24M | 2.37% |
23,400
-8,600
| -27% | -$1.49M |
2018 Q1
2 quarters
|
|
|
EIGR
20
DELISTED
Eiger BioPharmaceuticals, Inc.
EIGR
| $4.1M | 2.28% |
11,382
-3,232
| -22% | -$1.11M |
2017 Q4
3 quarters
|
|
21
PUT
Travere Therapeutics
TVTX
$4.88B
| $2.94M | 1.64% |
+102,300
| New | +$2.92M |
2018 Q3
0 quarters
|
|
22
Centene
CNC
$34B
| $2.88M | 1.6% |
39,750
+18,000
| +83% | +$1.25M |
2017 Q4
3 quarters
|
|
23
Axogen
AXGN
$2.12B
| $2.83M | 1.58% |
+76,741
| New | +$3.35M |
2018 Q3
0 quarters
|
|
24
Evolus
EOLS
$496M
| $2.58M | 1.44% |
+138,460
| New | +$3M |
2018 Q3
0 quarters
|
|
25
Gyre Therapeutics
GYRE
$711M
| $2.55M | 1.42% |
+31,541
| New | +$2.5M |
2018 Q3
0 quarters
|
|
Similar funds
SC
CCWM
CMA
RIS
MFS
GFI
PWM
CA
Prosight Management's Q3 2018 Portfolio in Review
As of Q3 2018, Prosight Management held 43 positions worth $179M, up 31% from $136M the previous quarter. Its ten largest holdings account for 60% of the portfolio.
Prosight Management deployed $32.6M of net new capital in Q3 2018, opening 12 new positions and adding to 10 existing holdings. Its largest new stake was Hanger Inc.: 1,199,602 shares worth $25M.
By sector, the portfolio is most concentrated in Healthcare at 98% of assets, up from 94% a quarter earlier, followed by Miscellaneous and Industrials.
On the sell side, the largest reduction was Cigna, an estimated $8.93M trimmed.
- Prosight Management's largest Q3 2018 buy was Hanger Inc.: 1,199,602 shares worth $25M.
- Prosight Management added most to Arena Pharmaceuticals Inc in Q3 2018, an estimated $4.24M increase.
- Prosight Management's biggest Q3 2018 reduction was Cigna, cutting an estimated $8.93M.
- Prosight Management fully exited Athenahealth, Inc. in Q3 2018, selling an estimated $6.55M.
- Prosight Management's ten largest holdings make up 60% of its $179M portfolio in Q3 2018.
- Prosight Management opened 12 new positions and closed 11 in Q3 2018.
- Prosight Management's portfolio value rose 31% quarter-over-quarter to $179M.
Based on Prosight Management's 13F filing for Q3 2018, filed 15 Nov 2018.